CellOxess to unveil in-vivo efficacy data for Fertilix®, a novel antioxidant formulation designed to prevent Sperm Oxidative Stress, at ESHRE 2015
Current estimates from the World Health Organization suggest that more than 1 in 5 couples worldwide seek medical assistance for their fertility. In 40-50% of couples, male factors contribute to the lowering of fertility potential. These factors include, among other things, reduced sperm motility, count, morphology, and poor DNA integrity. In fact, a recent report from the WHO indicated that average sperm concentrations in the male population have been falling 2% each year.
Scientists have now discovered that the body’s own uncontrolled metabolic species, commonly known as Reactive Oxygen Species (ROS), can affect the male reproductive tract resulting in a phenomenon called “Sperm Oxidative Stress” or SOS. Sperm health depends on a low oxidative state of the male reproductive tract to allow for normal growth and development in the testes. Accumulation of ROS in the male reproductive tract can overwhelm the body’s natural antioxidant defense mechanisms, consequently damaging the molecular components of sperm cells including membrane lipids, proteins and mitochondrial and nuclear DNA. This cellular damage can cause reduced sperm count and motility, poor morphology, and decreased DNA integrity which in turn may result in reduced male fertility, higher chance of miscarriage and the incorrect transmission of paternal DNA code.
Scientists at CellOxess Biotechnology believe they have found an effective solution to ameliorate SOS. After a decade of research and development by Dr. Parviz Gharagozloo and several teams of academic and industrial collaborators, the company formulated the first range of male preconceptual antioxidants, trademarked Fertilix®, to combat SOS. This June, at the prestigious European Society of Human Reproduction and Embryology’s annual meeting, CellOxess scientist Aron Moazamian will present the first in-vivo data demonstrating the efficacy of Fertilix® in mouse models of SOS.
Two independent labs, led by Professor Joël Drevet at Clermont University in France, and Professor Alfonso Gutiérrez-Adán at the INIA University of Madrid, verified that treatment of mice with Fertilix® prevented DNA damage, restored pregnancy rates to near normal levels and protected testicular tissue from the damaging effects of heat and ROS accumulation in established models of sperm oxidative stress. The official conference abstract may be found here.
These groundbreaking results will be presented in detail at the ESHRE Annual Conference in Lisbon, Portugal, at 15:45 on June 16th in Room Braga of the International Lisbon Fair; http://www.eshre2015.eu/.
It is fitting that CellOxess will also be showcasing Fertilix® for the first time in Europe at the world’s most prestigious reproductive conference. Several representatives, including Dr. Gharagozloo himself, will be present to discuss interest in the dietary supplement and opportunities for collaboration.
For more information, visit www.celloxess.com and www.fertilix.com, or visit booth #F10 from June 14th-17th on the conference floor.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.